Literature DB >> 30844711

Recent advances in the regulation of testicular germ cell tumors by microRNAs.

Aalia Batool1, Xi-Ming Liu2, Cui-Lian Zhang3, Cui-Fang Hao4, Su-Ren Chen5, Yi-Xun Liu1.   

Abstract

Testicular germ cell tumors (TGCTs) are generally rare but represent the most common solid tumors in young men. They are classified broadly into seminoma, which resemble primordial germ cells (PGCs), and non-seminoma, which are either undifferentiated (embryonic carcinoma) or differentiated (teratoma, yolk sac tumor, choriocarcinomas) patterning. A widespread role for microRNAs (miRNAs), in diverse molecular processes driving initiation and progression of various types of TGCTs has been recently studied. We discuss the involvement of different miRNAs in the development and progression of different types of TGCTs. Moreover, we highlight the aberrant expression of miRNAs in TGCTs and several targets, which may define miRNAs as oncomiRs or tumor suppressors. A better understanding of miRNA biology may ultimately yield further insight into the molecular mechanisms of tumorigenesis and new therapeutic strategies against TGCTs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30844711     DOI: 10.2741/4749

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  3 in total

1.  LINC00313 regulates the metastasis of testicular germ cell tumors through epithelial-mesenchyme transition and immune pathways.

Authors:  Zhizhong Liu; Bairong Fang; Jian Cao; Qianyin Zhou; Fang Zhu; Liqing Fan; Lei Xue; Chuan Huang; Hao Bo
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  Serum Level of microRNA-375-3p Is Not a Reliable Biomarker of Teratoma.

Authors:  Gazanfer Belge; Francesca Grobelny; Cord Matthies; Arlo Radtke; Klaus-Peter Dieckmann
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

3.  microRNA-196a-5p inhibits testicular germ cell tumor progression via NR6A1/E-cadherin axis.

Authors:  Xiaowen Liu; Ziling Fan; Ye Li; Zhilan Li; Zhuan Zhou; Xuehui Yu; Jingyu Wan; Ziqian Min; Lifang Yang; Dan Li
Journal:  Cancer Med       Date:  2020-10-09       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.